- United States
- United Kingdom
Consulte evidencias clínicas sobre los métodos quirúrgicos y pruebas de diagnóstico más avanzados para el tratamiento de patologías anorrectales.
A systematic review comparing transanal haemorrhoidal de-arterialisation to stapled haemorrhoidopexy in the management of haemorrhoidal disease - A systematic review comparing transanal haemorrhoidal de-arterialisation to stapled haemorrhoidopexy in the management of haemorrhoidal disease - THDLAB - ES
A systematic review comparing transanal haemorrhoidal de-arterialisation to stapled haemorrhoidopexy in the management of haemorrhoidal disease
Sajid M.S., Parampalli U., Whitehouse P., Sains P., McFall M. R., Baig M. K. Techniques in Coloproctology volume 16, pages1–8(2012)
The aim of this study was to systematically analyse the clinical trials on the effectiveness of transanal haemorrhoidal de-arterialisation (THD) and stapled haemorrhoidopexy (SH) in the management of haemorrhoidal disease (HD).
Clinical trials on the effectiveness of THD and SH in the management of HD were analysed systematically using RevMan®, and combined outcomes were expressed as risk ratio (RR) and mean difference (MD).
Three randomised, controlled trials encompassing 150 patients were analysed systematically. There were 80 THD patients and 70 SH patients. There was no significant heterogeneity (P = 0.40) among included trials. Therefore, in the fixed effects model, THD and SH were statistically equivalent in terms of treatment success rate (P = 0.19), operation time (P = 0.55), postoperative complications (P = 0.11) and recurrence (P = 0.46) of HD. THD was associated with significantly less postoperative pain (MD, −2.00; 95% CI, −2.06, −1.94; z = 63.59; P < 0.00001) compared to SH.
Both THD and SH are equally effective and can be attempted for the management of HD. However, THD is associated with significantly lesser postoperative pain and therefore may be considered a preferred procedure. This conclusion is based only on treating 150 patients by THD or SH in three moderate-quality randomised trials. A major, multicenter, randomised trial is required to validate this conclusion and investigate other variables like hospital stay, cost-effectiveness and health-related quality of life measurement.